Morbilliform Drug Reaction with Histologic Features of Pustular Dermatosis Associated with Bryostatin-1

October 2003 | Volume 2 | Issue 5 | Case Reports | 557 | Copyright © October 2003

Jennifer M. Krejci-Manwaring, MD; Melissa A. Bogle, MD and Hafeez A, Diwan, MD

Abstract
Bryostatin-1 is a new chemotherapeutic agent that inhibits protein kinase C. The most common side effect and the dose limiting toxicity is myalgia. The cutaneous side effects reported during the phase I and II trials were alopecia, mucositis, nonspecific “rash,” “bronzing,” and hyperpigmentation in sun exposed areas. No specific acute drug eruptions have been reported. We present the first reported case of a morbilliform drug eruption with histologic features of intraepidermal and subcorneal spongiotic pustules containing eosinophils secondary to bryostatin-1.